Celldex Therapeutics Inc (CLDX)

3.33
NASDAQ : Health Care
Prev Close 3.27
Day Low/High 3.22 / 3.33
52 Wk Low/High 2.85 / 5.13
Avg Volume 1.93M
Exchange NASDAQ
Shares Outstanding 123.21M
Market Cap 402.91M
EPS -1.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week of CLDX March 17th Options Trading

First Week of CLDX March 17th Options Trading

Investors in Celldex Therapeutics, Inc. saw new options become available this week, for the March 17th expiration.

Are People Finally Noticing?

Recognition of the market's inertia seems to be growing.

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

A look back at the year's worth of Adam Feuerstein's biotech tweets.

Celldex Presents Data On CDX-1140, A Novel CD40 Agonist Antibody For Hematologic And Solid Malignancies, At The American Society Of Hematology (ASH) Annual Meeting

Celldex Presents Data On CDX-1140, A Novel CD40 Agonist Antibody For Hematologic And Solid Malignancies, At The American Society Of Hematology (ASH) Annual Meeting

Additional investigator-sponsored presentations on varlilumab, CDX-301 and CDX-1401 also at ASH

Commit To Buy Celldex Therapeutics At $3, Earn 23.3% Using Options

Commit To Buy Celldex Therapeutics At $3, Earn 23.3% Using Options

Investors considering a purchase of Celldex Therapeutics, Inc. shares, but cautious about paying the going market price of $4.17/share, might benefit from considering selling puts among the alternative strategies at their disposal.

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.

Celldex Expands Antibody And Immuno-Oncology Portfolio With The Acquisition Of Kolltan Pharmaceuticals

Celldex Expands Antibody And Immuno-Oncology Portfolio With The Acquisition Of Kolltan Pharmaceuticals

--Conference call to be held at 4:30 p.m. Eastern Time today--

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) reported a narrower loss than analysts had anticipated for the 2016 second quarter after Monday's closing bell.

Celldex Therapeutics (CLDX) Is Strong On High Volume Today

Celldex Therapeutics (CLDX) Is Strong On High Volume Today

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate

Celldex Reports Second Quarter 2016 Results

Celldex Reports Second Quarter 2016 Results

Conference Call Scheduled for Monday, August 8 at 4:30 p.m. Eastern Time

Celldex To Report Second Quarter 2016 Financial Results And Host Corporate 2016 Objectives Update Call

Celldex To Report Second Quarter 2016 Financial Results And Host Corporate 2016 Objectives Update Call

Conference Call Scheduled for Monday, August 8 at 4:30 p.m. Eastern Time

Celldex Therapeutics Initiates Phase 1/2 Clinical Trial Of New Product Candidate CDX-014 In Advanced Renal Cell Carcinoma

Celldex Therapeutics Initiates Phase 1/2 Clinical Trial Of New Product Candidate CDX-014 In Advanced Renal Cell Carcinoma

Antibody-drug conjugate directed to TIM-1, a novel target upregulated in several cancers

Celldex Therapeutics (CLDX) In A Perilous Reversal

Celldex Therapeutics (CLDX) In A Perilous Reversal

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "perilous reversal" (up big yesterday but down big today) candidate

Celldex Therapeutics (CLDX) Marked As A Dead Cat Bounce Stock

Celldex Therapeutics (CLDX) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a "dead cat bounce" (down big yesterday but up big today) candidate

Celldex Therapeutics' CDX-1401, CDX-301 Combination Generates Potent NY-ESO-1 Immune Responses In Patients With Melanoma

Celldex Therapeutics' CDX-1401, CDX-301 Combination Generates Potent NY-ESO-1 Immune Responses In Patients With Melanoma

CDX-301's utility as a dendritic cell growth factor in combination therapy established

Immunomedics Kicked Out of Prestigious ASCO Cancer Conference

Immunomedics Kicked Out of Prestigious ASCO Cancer Conference

Immunomedics was caught trying to sneak old, previously presented clinical data on its triple-negative breast cancer drug IMMU-132 into the American Society of Clinical Oncology (ASCO) annual meeting.